Effects of lorazepam on visual perceptual abilities

“…The advantage in memorizing visual stimuli possibly owe to improvement in visual processing (see Furey et al, 2008a) elicited by this drug and observed as a shortening of IT. It also may relate to the improvement found in executive mechanisms because even simple visuospatial tasks seem to heavily implicate central executive functioning (Baddeley et al, 1999;Miyake et al, 2001;Pompéia et al, 2008).…”

Section: Discussionmentioning

confidence: 95%

Acute cognitive effects of donepezil in young, healthy volunteers

Zaninotto

Bueno

Pradella-Hallinan

et al. 2009

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Studies of DSST performance relative to placebo have shown effect sizes (Cohen’s d ) of 0.25–0.5 for diphenhydramine (Roth et al, 1987) and lorazepam (Pompeia et al, 2008), and 0.68 in people whose blood alcohol concentration is 0.09% (Mattila and Mattila-Evenden, 1997; national guidelines usually stipulate an upper threshold of either 0.05 or 0.08%; ). Importantly, while the effects of these agents cease once the drug effects wear off, the effects of cognitive dysfunction in chronic MDD are far more persistent.…”

Section: Discussionmentioning

confidence: 99%

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials

McIntyre¹,

Harrison²,

Loft³

et al. 2016

IJNPPY

151

View full text Add to dashboard Cite

Background:Management of cognitive deficits in Major Depressive Disorder (MDD) remains an important unmet need. This meta-analysis evaluated the effects of vortioxetine on cognition in patients with MDD.Methods:Random effects meta-analysis was applied to three randomized, double-blind, placebo-controlled 8-week trials of vortioxetine (5–20mg/day) in MDD, and separately to two duloxetine-referenced trials. The primary outcome measure was change in Digit Symbol Substitution Test (DSST) score. Standardized effect sizes (SES) versus placebo (Cohen’s d) were used as input. Path analysis was employed to determine the extent to which changes in DSST were mediated independently of a change in Montgomery-Åsberg Depression Rating Scale (MADRS) score. Meta-analysis was applied to MADRS-adjusted and -unadjusted SES values. Changes on additional cognitive tests were evaluated (source studies only).Results:Before adjustment for MADRS, vortioxetine separated from placebo on DSST score (SES 0.25–0.48; nominal p < 0.05) in all individual trials, and statistically improved DSST performance versus placebo in meta-analyses of the three trials (SES = 0.35; p < 0.0001) and two duloxetine-referenced trials (SES = 0.26; p = 0.001). After adjustment for MADRS, vortioxetine maintained DSST improvement in one individual trial (p = 0.001) and separation from placebo was maintained in meta-analyses of all three trials (SES = 0.24; p < 0.0001) and both duloxetine-referenced trials (SES 0.19; p = 0.01). Change in DSST with duloxetine failed to separate from placebo in individual trials and both meta-analyses. Change in DSST statistically favored vortioxetine versus duloxetine after MADRS adjustment (SES = 0.16; p = 0.04).Conclusions:Vortioxetine, but not duloxetine, significantly improved cognition, independent of depressive symptoms. Vortioxetine represents an important treatment for MDD-related cognitive dysfunction.

show abstract

Effects of lorazepam on visual perceptual abilities

Cited by 13 publications

References 63 publications

Acute lorazepam effects on neurocognitive performance

Acute lorazepam effects on neurocognitive performance

Acute cognitive effects of donepezil in young, healthy volunteers

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials

Contact Info

Product

Resources

About